No Picture
Los Angeles Biotech News

REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID

LOS ANGELES–(BUSINESS WIRE)– #REMAP_CAP–Global Coalition for Adaptive Research (LOS ANGELES, CA) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) — The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (U… […]

No Picture
Los Angeles Biotech News

The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome (“IBS”) Diagnostic-Guided Therapy (“DGT”) clinical trial

IRVINE, Calif., June 29, 2020 (GLOBE NEWSWIRE) — Biomerica Inc. (NASDAQ: BMRA) today announced it has signed a definitive agreement with the University of Texas Health Science Center at Houston (“UTH”) to join the clinical trial for Biomerica’s new … […]

No Picture
Los Angeles Biotech News

New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (nicotinamide riboside or NR) in bolstering cell… […]

No Picture
Los Angeles Biotech News

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of Health

TORRANCE, Calif., June 29, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting market… […]

No Picture
Los Angeles Biotech News

Sekar Kathiresan showcases historic monkey data in hunt for a once-and-done gene editing approach to prevent heart attacks

In a first for CRISPR — a field that’s seen quite a few historic moves in the past couple of years — scientists have slashed cholesterol and lipid levels in monkeys using a technique known as base editing, generating crucial proof-of-concept for both t… […]

No Picture
Los Angeles Biotech News

Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it?

In 2006, a German biotech developed what they called a “superagonist” for CD28, a pocket on T cells that in theory could be used to stimulate their ability to fight cancer. They put it in 6 healthy volunteers, each of whom became critically ill within … […]

No Picture
Los Angeles Biotech News

NantHealth Announces Research Results that Advances Understanding of Tumor Treatment Resistance

CULVER CITY, Calif.–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the publication of a study in JCI Insight, a peer-reviewed journal dedicated to biomedical research… […]

No Picture
Los Angeles Biotech News

NantHealth Announces Research Results that Advances Understanding of Tumor Treatment Resistance

CULVER CITY, Calif.–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the publication of a study in JCI Insight, a peer-reviewed journal dedicated to biomedical research… […]